Checkpoint Therapeutics Announces $10 Million Registered Direct Offering Priced At-the-Market
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a…
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
Management to host conference call and webcast at 4:30 pm ET on that day Boca…
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”)…
CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) — Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”)…
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Nes-Ziona, Israel, July 31, 2023 (GLOBE NEWSWIRE) — Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”),…
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design…
Acquisition aims to strengthen BioNTech’s pioneering position in the field of AI-powered drug discovery, design…
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
SYDNEY, Australia, July 31, 2023 (GLOBE NEWSWIRE) — Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q)…
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing…
SAN FRANCISCO, July 31, 2023 (GLOBE NEWSWIRE) — Neurona Therapeutics, a clinical-stage biotherapeutics company advancing…
CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva”…
CUPERTINO, Calif., July 31, 2023 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva”…
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing…
Collaboration Broadens Reach of VAZKEPA to Additional Ten Countries Leveraging Lotus’ Established Commercial and Marketing…
Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of…
Independent Data Monitoring Committee recommended REVEAL Phase 1/2 trial continuation and proceeding with dosing of…
Media Release Late-stage & registrational trial progress: TACTI-004 Phase III – Positive feedback received from…